[High-dose chemotherapy and autologous bone marrow transplantation in high-grade metastatic sarcomas].
Metastatic sarcomas have a poor prognosis with current therapeutic regimens. High dose chemotherapy (HDC) has proved to be efficient in a selected group of solid tumors. Nine patients with high grade metastatic sarcomas were treated with HDC followed by autologous bone marrow transplantation. Four patients received HDC as a consolidation of the complete response (CR) obtained with chemotherapy (CT) and two of them were free from disease at 27 and 41 months, respectively. Other four patients had a disease total or partially refractory to conventional CT, and in one case the sensitivity to the chemotherapeutical agents was unknown. In these five cases a partial response was observed in two of the three who had measurable response parameters, but all of them died because of disease progression in a short period of time. These results suggest that there are active HDC schedules on metastatic sarcomas, but its possible benefit would be limited to the consolidation of a CR obtained with previous CT. HDC is a therapeutical alternative under investigation in patients with metastatic sarcomas with an indication that could be extended to cover localized sarcomas with poor prognosis.
Mesía
R
R
Servicio de Oncología Médica, Hospital de la Santa Creu i Sant Pau., Barcelona.
Solá
C
C
López Pousa
A
A
Mendoza
L
L
Bellet
M
M
Andrés
L
L
López López
J J
JJ
D000293:Adolescent; D000328:Adult; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000008:administration & dosage* / Q000009:adverse effects; D016026:Bone Marrow Transplantation / Q000009:adverse effects; D003131:Combined Modality Therapy; D005260:Female; D006801:Humans; D008297:Male; D011379:Prognosis; D012074:Remission Induction; D012509:Sarcoma / Q000401:mortality / Q000556:secondary* / Q000628:therapy*; D014182:Transplantation, Autologous
Quimioterapia con altas dosis y trasplante autólogo de médula ósea en sarcomas de alto grado metastásicos.